TFRC and cancer: Among them, Transferrin–drug conjugates (e.g., Tf–doxorubicin) may selectively kill cancer cells and overcome multi drug resistance in leukemia [70] and breast cancer [71], anti-CD71 antibodies may act therapeutically [68] and iron chelators (such as deferasirox, triapine and others) have been shown to exhibit anticancer activity in preclinical/clinical settings [72,73].